Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC)

Lowe DM., Zhang S., Ellis S., Buggiotti L., Miller C., Harris V., Shields AM., Richter AG., Ashmore E., Yu L-M., Khoo S., Hobbs FDR., Little P., Butler CC., Breuer J., Standing JF., Ahmed H., Andersson M., Bateman C., Berry NS., Butler D., Cureton L., Davies JC., Detry MA., Dobson M., Dorward J., Png ME., Evans P., Fitzgerald M., Francis N., Gbinigie OA., Hart ND., Hayward G., Holmes J., Jani BD., Lown M., Hood K., Marion J., McKenna M., Mort S., Nguyen-Van-Tam JS., Patel MG., Patil M., Petrou S., Rahman NM., Richards DB., Saunders CT., Saville BR., Carson-Stevens A., Thomas NPB., Ustianowski A., van Hecke O., and ., Allen J., Ashford F., Bayzid N., Brown J., Burns D., Dinally M., Hadley E., Hatcher J., McHugh T., Thalasselis C., Tomlinson M., Uwenedi G., Yongblah F.

DOI

10.1016/j.lanmic.2026.101360

Type

Journal article

Publisher

Elsevier BV

Publication Date

2026-04-01T00:00:00+00:00

Pages

101360 - 101360

Total pages

0

Permalink More information Close